The report highlights Daiichi Sankyo's commitment to sustainable improvement of corporate value, focusing on their 2025 vision of becoming a ""Global Pharma Innovator with Competitive Advantage in Oncology."" The report details the company's efforts in developing innovative pharmaceuticals, addressing diverse medical needs, and strengthening their business foundations through robust compliance management, corporate governance, and environmental stewardship. The report also highlights Daiichi Sankyo's commitment to the Sustainable Development Goals (SDGs) and their efforts to combat the COVID-19 pandemic, including research and development of vaccines and therapeutic agents, ensuring a stable supply of pharmaceuticals, and promoting access to healthcare. The report includes a detailed overview of the company's value creation process, materiality assessment, risk management, and corporate governance structure, showcasing their commitment to transparency and stakeholder engagement.
Go back to company
Daiichi Sankyo Co Ltd 2020 Value Report
Issuing Company Daiichi Sankyo Co., Ltd.
Report Type Sustainability Report
Report Language EN
Report Filesize 4.3 MB
No. of Pages 106 pages
Reporting periodApril 1, 2019-March 31, 2020
Report EditionUnknown
Assurance Provider KPMG AZSA Sustainability Co., Ltd.
Reporting Standards GRI; SASB; UNSDGs
Materiality Assessmenttrue